You are here
FDA Accepts Erlotinib Application as a Treatment for Patients With Advanced Non-Small Cell Lung Cancer
OSI also announced that Tarceva(TM) has been granted priority review classification by the FDA. Based on this priority review status, the FDA has six months from the NDA receipt date, or until January 30, 2005, to take action on the NDA filing.
The Tarceva NDA was previously granted Pilot 1 Status under the FDA's Pilot 1 Program for Continuous Marketing Applications, a new program designed for investigational products that have been given Fast Track status, such as Tarceva(TM), and that have demonstrated significant promise in clinical trials as a therapeutic advance over available therapy for a disease or condition. Under the Pilot 1 status, the FDA is committed to reviewing each unit of the NDA within six months of each unit submission. The NDA filing for Tarceva(TM) is based on a pivotal Phase III trial known as BR.21. OSI completed the NDA submission in July 2004.
The BR.21 trial was a double-blind, placebo-controlled study which included 731 patients with advanced NSCLC who had previously received one or two prior chemotherapy regimens. Tarceva(TM) demonstrated a 42 percent improvement in median survival and improved one-year survival by 45 percent. The trial also demonstrated statistically significant improvement in all secondary endpoints of the trial including time to symptom deterioration, progression-free survival and response rate. The study results make Tarceva(TM) the first and only targeted therapy to demonstrate an improvement in survival for NSCLC patients. Detailed results of the trial were presented in June at the 40th Annual American Society of Clinical Oncology (ASCO) meeting in New Orleans. The global study was conducted by the National Cancer Institute of Canada Clinical Trials Group based at Queen's University in collaboration with OSI Pharmaceuticals.
In line with previous clinical studies, adverse events that occurred more often with patients treated with Tarceva(TM) in the pivotal trial included rash and diarrhea, which were generally mild to moderate in severity. Seventy-five percent of patients receiving Tarceva(TM) exhibited rash (versus 17 percent in the placebo group) and 54 percent of patients receiving Tarceva(TM) experienced diarrhea (versus 18 percent for placebo). Dose reductions occurred for rash and diarrhea only in the Tarceva(TM) arm, six percent and one percent, respectively. In the pivotal study, severe pulmonary events, including potential cases of interstitial lung events, were infrequent and were equally distributed between treatment arms.
Tarceva is a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway, which is one of the factors critical to cell growth in many cancers. HER1, also known as EGFR, is a key component of the HER signaling pathway, which plays a role in the formation and growth of numerous cancers. Tarceva(TM) is designed to inhibit the tyrosine kinase activity of the HER1 signaling pathway inside the cell, which may block tumor cell growth. Clinical trials of Tarceva(TM) are being conducted in other solid tumors, such as pancreatic, ovarian, colorectal, head and neck, kidney, brain and gastrointestinal cancers. Tarceva(TM) is currently being evaluated in an extensive clinical development program by a global alliance of OSI Pharmaceuticals, Genentech, and Roche.
About Non-Small Cell Lung Cancer
According to the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial cancer each year, causing approximately 1.1 million deaths annually. According to the National Cancer Institute, lung cancer is the single largest cause of cancer deaths in the United States and is responsible for nearly 30 percent of cancer deaths in the country. NSCLC is the most common form of lung cancer and accounts for almost 80 percent of cases.
Source: OSI Pharmaceuticals, Inc.